Trials / Recruiting
RecruitingNCT06238401
An Open-label, Multi-center, Dose-escalation and Cohort Expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of ACR246 in Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 77 (estimated)
- Sponsor
- Hangzhou Adcoris Biopharmacy Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The goal of the study is to evaluate the safety and tolerability of ACR246 in patients with advanced solid tumors, to determine the maximum tolerated dose (MTD) and Phase II recommended dose (RP2D) of ACR246.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ACR246 for injection | 80 mg/vial |
Timeline
- Start date
- 2024-10-29
- Primary completion
- 2026-05-30
- Completion
- 2026-11-30
- First posted
- 2024-02-02
- Last updated
- 2025-11-24
Locations
6 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06238401. Inclusion in this directory is not an endorsement.